Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2019
Dec. 31, 2018
Current Assets    
Cash and cash equivalents $ 23,528,241 $ 24,637,295
Other receivable from joint venture 358,801 93,253
Prepaid expenses and other current assets 194,059 36,745
Total Current Assets 24,081,101 24,767,293
Other Assets    
Patent costs 1,686,182 1,577,421
Total Assets 25,767,283 26,344,714
Current Liabilities    
Accounts payable and accrued liabilities 614,622 258,056
Investee losses in excess of investment 73,295 218,263
Total Current Liabilities 687,917 476,319
Commitments and contingencies - (Note 5)
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares:
Common stock, $0.001 par value, 100,000,000 authorized, 36,149,325 shares and 32,862,090 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively 36,149 32,863
Additional paid-in capital 131,647,886 129,329,674
Accumulated deficit (106,608,149) (103,497,622)
Total Stockholders' Equity 25,079,366 25,868,395
Total Liabilities and Stockholders' Equity 25,767,283 26,344,714
Convertible Series A Preferred Stock [Member]    
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares: 813 813
Convertible Series B Preferred Stock [Member]    
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares: $ 2,667 $ 2,667